Cutaneous and Ganglion Sarcoidosis Induced by Polycaprolactone Facial Filler: A New Expression of ASIA Syndrome?

Abstract

Dermal fillers are applied using a minimally invasive technique with a good safety profile. However, they can have side effects. We present the case of a patient who, 2 months after undergoing polycaprolactone (Ellansé®) injections, developed nodular facial and nodal lesions that were compatible with sarcoidosis on histology. This complication has not been previously described for polycaprolactone and could be the expression of an autoimmune syndrome induced by adjuvants.

The Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA), Associated with Renal Compromise and Cutaneous Calcinosis: A Case Report and Literature Review

“…Additionally, systemic autoimmune disorders and ANCA-positive vasculitis were ruled out by the negativity of antibodies for these entities, except for ANA, which, while positive, did not meet the ACR/EULAR criteria for systemic lupus erythematosus, and the patient did not have evidence suggesting active connective tissue disease. Having ruled out all previously mentioned conditions, the classic criteria for ASIA syndrome proposed by Shoenfeld and Agmon-Levin were applied, and it was found that 2 major criteria and one minor criterion were met, leading to the diagnosis of ASIA syndrome [ 4 , 15 , 16 ].…”

First reported case of delayed‐type hypersensitivity reaction to non‐hyaluronic acid Polycaprolactone dermal filler following COVID‐19 vaccination: A case report and a review of the literature

“… 8 In comparison, treatment for filler‐induced granulomas consists of observing, massaging, saline or water dilution, intralesional steroids injection, oral antibiotics administration, curettage, and lesion removal. 8 , 9 , 10 , 11 Moreover, methotrexate has been used in a case of eruptive granuloma following PCL filler placement. 10 In our case, topical and intralesional steroids were prescribed and a significant improvement of the lesions was observed.…”